Walleye Capital
NTLA icon

Walleye Capital’s Intellia Therapeutics NTLA Stock Holding History

Walleye Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$183K Buy
14,300
+5,700
+66% +$72.6K ﹤0.01% 3388
2025
Q4 		$77.3K Sell
8,600
-249,100
-97% -$3.43M ﹤0.01% 3954
2025
Q3 		$4.45M Sell
257,700
-49,500
-16% -$610K 0.02% 995
2025
Q2 		$2.88M Buy
307,200
+269,200
+708% +$2.21M 0.01% 1239
2025
Q1 		$270K Buy
38,000
+17,200
+83% +$174K ﹤0.01% 3027
2024
Q4 		$243K Sell
20,800
-24,000
-54% -$375K ﹤0.01% 3609
2024
Q3 		$921K Buy
44,800
+22,300
+99% +$514K ﹤0.01% 2734
2024
Q2 		$504K Buy
22,500
+6,500
+41% +$155K ﹤0.01% 3510
2024
Q1 		$440K Sell
16,000
-12,800
-44% -$356K ﹤0.01% 3307
2023
Q4 		$878K Buy
28,800
+21,200
+279% +$609K ﹤0.01% 2466
2023
Q3 		$240K Sell
7,600
-6,300
-45% -$244K ﹤0.01% 3407
2023
Q2 		$567K Sell
13,900
-13,500
-49% -$547K ﹤0.01% 2342
2023
Q1 		$1.02M Sell
27,400
-19,300
-41% -$757K 0.02% 1157
2022
Q4 		$1.63M Buy
46,700
+38,000
+437% +$1.81M 0.03% 698
2022
Q3 		$487K Buy
+8,700
New +$540K 0.01% 1490
2020
Q2 		– Sell
-100
Closed -$1K – 857
2020
Q1 		$1K Sell
100
-7,200
-99% -$97K ﹤0.01% 827
2019
Q4 		$107K Sell
7,300
-3,000
-29% -$41.7K 0.01% 1345
2019
Q3 		$138K Sell
10,300
-200
-2% -$3.19K 0.01% 1334
2019
Q2 		$172K Sell
10,500
-19,500
-65% -$307K 0.02% 1028
2019
Q1 		$512K Buy
+30,000
New +$447K 0.08% 378

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Walleye Capital's NTLA Position: Q1 2026 in Review

Walleye Capital sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 6,580 shares — an estimated $83.8K sold.

Walleye Capital first reported a position in NTLA in Q3 2019 and held it in 17 quarters. The position peaked at $6.2M in Q4 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Walleye Capital reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 6,580 Intellia Therapeutics shares in Q1 2026, an estimated $83.8K.
  • Walleye Capital first reported a position in Intellia Therapeutics in Q3 2019 and held it in 17 quarters.
  • Walleye Capital's Intellia Therapeutics position peaked at $6.2M in Q4 2023.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.